NCT02468193View on ClinicalTrials.gov

Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

June 7, 2018

Study Completion Date

October 29, 2018

Conditions
Cushing's SyndromeEctopic Corticotropin SyndromeAdrenal AdenomaAdrenal CarcinomaAIMAHPPNAD
Interventions
DRUG

Osilodrostat

Osirodrostat 1mg, 5mg \& 10mg in the form of film-coated tablets was used for oral administration.

Trial Locations (4)

960 1295

Novartis Investigative Site, Fukushima

245-8575

Novartis Investigative Site, Yokohama

980 8574

Novartis Investigative Site, Sendai

260 8677

Novartis Investigative Site, Chiba

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY